



Australian Government

Department of Health and Ageing

**SCHEDULE OF PHARMACEUTICAL
BENEFITS**

SUMMARY OF CHANGES

EFFECTIVE 1 September 2013

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 September 2013. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 September 2013 and are included, where applicable, in prices published in the Schedule —

Dispensing Fees:	Ready-prepared	\$6.63
	Dangerous drug fee	\$2.71
	Extemporaneously-prepared	\$8.67
	Allowable additional patient charge*	\$4.11
Additional Fees (for safety net prices):	Ready-prepared	\$1.13
	Extemporaneously-prepared	\$1.48
Patient Co-payments:	General	\$36.10
	Concessional	\$5.90
Safety Net Thresholds:	General	\$1390.60
	Concessional	\$354.00
Safety Net Card Issue Fee:		\$9.06

*The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

SUMMARY OF CHANGES

Additions

Addition – Item

2744K	Apixaban , apixaban 2.5 mg tablet, 60 (<i>Eliquis</i>)
2735Y	Apixaban , apixaban 5 mg tablet, 60 (<i>Eliquis</i>)
2753X	Dabigatran , dabigatran etexilate 110 mg capsule, 60 (<i>Pradaxa</i>)
2769R	Dabigatran , dabigatran etexilate 150 mg capsule, 60 (<i>Pradaxa</i>)
2784M	Degarelix , degarelix 80 mg injection [1 x 80 mg vial] (&) inert substance diluent [1 syringe], 1 pack (<i>Firmagon 80mg</i>)
2785N	Degarelix , degarelix 120 mg injection [2 x 120 mg vials] (&) inert substance diluent [2 syringes], 1 pack (<i>Firmagon 120mg</i>)
2742H	Flutamide , flutamide 250 mg tablet, 30 (<i>Flutamide MYLAN</i>)
2755B	Tafloprost , tafloprost 0.0015% eye drops, 30 x 0.3 mL unit doses (<i>Saflutan</i>)
2748P	Tafloprost , tafloprost 0.0015% eye drops, 30 x 0.3 mL unit doses (<i>Saflutan</i>)

Addition – Brand

8504N	<i>Candesartan/HCT Sandoz, SZ</i> – Candesartan + Hydrochlorothiazide , candesartan cilexetil 16 mg + hydrochlorothiazide 12.5 mg tablet, 30
8504N	<i>Pharmacor Candesartan HCT 16/12.5, CR</i> – Candesartan + Hydrochlorothiazide , candesartan cilexetil 16 mg + hydrochlorothiazide 12.5 mg tablet, 30
9314F	<i>Candesartan/HCT Sandoz, SZ</i> – Candesartan + Hydrochlorothiazide , candesartan cilexetil 32 mg + hydrochlorothiazide 12.5 mg tablet, 30
9314F	<i>Pharmacor Candesartan HCT 32/12.5, CR</i> – Candesartan + Hydrochlorothiazide , candesartan cilexetil 32 mg + hydrochlorothiazide 12.5 mg tablet, 30
9315G	<i>Candesartan/HCT Sandoz, SZ</i> – Candesartan + Hydrochlorothiazide , candesartan cilexetil 32 mg + hydrochlorothiazide 25 mg tablet, 30
9315G	<i>Pharmacor Candesartan HCT 32/25, CR</i> – Candesartan + Hydrochlorothiazide , candesartan cilexetil 32 mg + hydrochlorothiazide 25 mg tablet, 30
8315P	<i>Cefepime-AFT, AE</i> – Cefepime , CEFEPIME Powder for injection 1 g (as hydrochloride), 1
8316Q	<i>Cefepime-AFT, AE</i> – Cefepime , CEFEPIME Powder for injection 2 g (as hydrochloride), 1
8002E	<i>Auro-Famciclovir 250, DO</i> – Famciclovir , famciclovir 250 mg tablet, 21
8217L	<i>Auro-Famciclovir 250, DO</i> – Famciclovir , famciclovir 250 mg tablet, 56
8729K	<i>Granisetron-AFT, AE</i> – Granisetron , granisetron 3 mg/3 mL injection, 1 x 3 mL ampoule
8730L	<i>Granisetron-AFT, AE</i> – Granisetron , granisetron 3 mg/3 mL injection, 1 x 3 mL ampoule
1512N	<i>Hydroxychloroquine Actavis, GM</i> – Hydroxychloroquine , hydroxychloroquine sulfate 200 mg tablet, 100
8627C	<i>Pharmacor Montelukast 4, CR</i> – Montelukast , montelukast 4 mg tablet: chewable, 28
8628D	<i>Pharmacor Montelukast 5, CR</i> – Montelukast , montelukast 5 mg tablet: chewable, 28

Deletions

Deletion – Item

1648R	Misoprostol , misoprostol 200 microgram tablet, 120 (<i>Cytotec</i>)
2003K	Salbutamol , salbutamol 0.5% (5 mg/mL) inhalation: solution, 1 x 30 mL bottle (<i>Pfizer Australia Pty Ltd</i>)

Deletion – Brand

8019C	<i>Cyprohexal, SZ</i> – Cyproterone , cyproterone acetate 100 mg tablet, 50
1269T	<i>Cyprohexal, SZ</i> – Cyproterone , cyproterone acetate 50 mg tablet, 20
1270W	<i>Cyprohexal, SZ</i> – Cyproterone , cyproterone acetate 50 mg tablet, 50
2430X	<i>Formet 500, QA</i> – Metformin , metformin hydrochloride 500 mg tablet, 100
1801T	<i>Formet 850, QA</i> – Metformin , metformin hydrochloride 850 mg tablet, 60
3010K	<i>Noroxin, MK</i> – Norfloxacine , norfloxacine 400 mg tablet, 14
1596B	<i>Zofran, AS</i> – Ondansetron , ondansetron 4 mg/2 mL injection, 1 x 2 mL ampoule
8226Y	<i>Zofran, AS</i> – Ondansetron , ondansetron 4 mg/2 mL injection, 1 x 2 mL ampoule
1597C	<i>Zofran, AS</i> – Ondansetron , ondansetron 8 mg/4 mL injection, 1 x 4 mL ampoule
8227B	<i>Zofran, AS</i> – Ondansetron , ondansetron 8 mg/4 mL injection, 1 x 4 mL ampoule
1968N	<i>Acquin 5, QA</i> – Quinapril , quinapril 5 mg tablet, 30
1969P	<i>Acquin 10, QA</i> – Quinapril , quinapril 10 mg tablet, 30
1970Q	<i>Acquin 20, QA</i> – Quinapril , quinapril 20 mg tablet, 30
8508T	<i>Rabeprazole Actavis 20, TA</i> – Rabeprazole , rabeprazole sodium 20 mg tablet: enteric, 30 tablets
8509W	<i>Rabeprazole Actavis 20, TA</i> – Rabeprazole , rabeprazole sodium 20 mg tablet: enteric, 30 tablets
8899J	<i>Actonel Combi, SW</i> – Risedronate (&) Calcium Carbonate , risedronate sodium 35 mg tablet [4 tablets] (&) calcium (as carbonate) 500 mg tablet [24 tablets], 28

8144P *Sumagran 50, QA* – **Sumatriptan**, SUMATRIPTAN Tablet 50 mg (as succinate), 2

Alterations

Alteration – Brand Name

From:

9155W *Duloxetine DR GH, GQ* – **Duloxetine**, duloxetine 30 mg capsule: enteric, 28

To:

9155W *Duloxetine GH, GQ* – **Duloxetine**, duloxetine 30 mg capsule: enteric, 28

From:

9156X *Duloxetine DR GH, GQ* – **Duloxetine**, duloxetine 60 mg capsule: enteric, 28

To:

9156X *Duloxetine GH, GQ* – **Duloxetine**, duloxetine 60 mg capsule: enteric, 28

Advance Notices

Advance Notices – Deletion of Item

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 November 2013:

1266P **Cyclophosphamide**, cyclophosphamide 50 mg tablet, 50 (*Cycloblastin*)

2103Q **Tiaprofenic Acid**, tiaprofenic acid 300 mg tablet, 60 (*Surgam*)

SECTION 100 – HIGHLY SPECIALISED DRUGS PROGRAM

Additions

Addition – Item

2758E **Filgrastim**, filgrastim 300 microgram/0.5 mL injection, 5 x 0.5 mL syringes (*Zarzio*) **(Public)**

2747N **Filgrastim**, filgrastim 300 microgram/0.5 mL injection, 5 x 0.5 mL syringes (*Zarzio*) **(Private)**

2783L **Filgrastim**, filgrastim 480 microgram/0.5 mL injection, 5 x 0.5 mL syringes (*Zarzio*) **(Public)**

2733W **Filgrastim**, filgrastim 480 microgram/0.5 mL injection, 5 x 0.5 mL syringes (*Zarzio*) **(Private)**

2736B **Raltegravir**, raltegravir 25 mg tablet: chewable, 60 (*Isentress*) **(Public)**

2743J **Raltegravir**, raltegravir 25 mg tablet: chewable, 60 (*Isentress*) **(Private)**

2760G **Raltegravir**, raltegravir 100 mg tablet: chewable, 60 (*Isentress*) **(Public)**

2754Y **Raltegravir**, raltegravir 100 mg tablet: chewable, 60 (*Isentress*) **(Private)**

SECTION 100 – OPIATE DEPENDENCE TREATMENT PROGRAM

Deletions

Deletion – Item

6470M **Buprenorphine + Naloxone**, buprenorphine 2 mg + naloxone 500 microgram tablet: sublingual, 28 tablets (*Suboxone*)

6471N **Buprenorphine + Naloxone**, buprenorphine 8 mg + naloxone 2 mg tablet: sublingual, 28 tablets (*Suboxone*)

REPATRIATION PHARMACEUTICAL BENEFITS

Additions

Addition – Note

Add the following note to all Smith & Nephew products listed under manufacturer B.S.N (code BV).

Smith & Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith & Nephew Customer Service on 13 13 60. Smith & Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.

This note addition applies to the BV brand under each of the following item codes:-

4790D, 4794H, 4654Y, 4662J, 4707R, 4708T, 4717G, 4718H, 4719J, 4727T, 4728W, 4729X, 4736G, 4748X, 4767X, 4780N, 4781P, 4782Q, 4783R

4781P 4782Q 4783R 4785W 4787Y 4788B 4789C

Deletions

Deletion – Item

4701K **Cotton Wool**, cotton wool roll, 100 g (*JJ 02013*)

4544E **Sunscreens**, SUNSCREENS Cream 100 g, 1 (*Hamilton Sunscreen Family Sunscreen Cream SPF 15*)

GENERAL PHARMACEUTICAL BENEFITS

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
APIXABAN								
<u>Authority required (STREAMLINED)</u>								
4269								
Prevention of stroke or systemic embolism								
The Clinical criteria is:								
Patient must have non-valvular atrial fibrillation,								
AND the Clinical criteria is:								
Patient must have one or more risk factors for developing stroke or systemic embolism.								
Risk factors for developing stroke or systemic ischaemic embolism are:								
(i) Prior stroke (ischaemic or unknown type), transient ischaemic attack or non-central nervous system (CNS) systemic embolism;								
(ii) age 75 years or older;								
(iii) hypertension;								
(iv) diabetes mellitus;								
(v) heart failure and/or left ventricular ejection fraction 35% or less.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
No increase in the maximum quantity or number of units may be authorised.								
<u>Note</u>								
No increase in the maximum number of repeats may be authorised.								
<u>Note</u>								
Special Pricing Arrangements apply.								
2744K NP	apixaban 2.5 mg tablet, 60	1	5	..	281.94	36.10	Eliquis	BQ
2735Y NP	apixaban 5 mg tablet, 60	1	5	..	101.40	36.10	Eliquis	BQ
DABIGATRAN								
<u>Authority required (STREAMLINED)</u>								
4269								
Prevention of stroke or systemic embolism								
The Clinical criteria is:								
Patient must have non-valvular atrial fibrillation,								
AND the Clinical criteria is:								
Patient must have one or more risk factors for developing stroke or systemic embolism.								
Risk factors for developing stroke or systemic ischaemic embolism are:								
(i) Prior stroke (ischaemic or unknown type), transient ischaemic attack or non-central nervous system (CNS) systemic embolism;								
(ii) age 75 years or older;								
(iii) hypertension;								
(iv) diabetes mellitus;								
(v) heart failure and/or left ventricular ejection fraction 35% or less.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
<u>Note</u>								
No increase in the maximum quantity or number of units may be authorised.								
<u>Note</u>								
No increase in the maximum number of repeats may be authorised.								
<u>Note</u>								
Special Pricing Arrangements apply.								
2753X NP	dabigatran etexilate 110 mg capsule, 60	1	5	..	96.12	36.10	Pradaxa	BY

GENERAL PHARMACEUTICAL BENEFITS

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
2769R NP	dabigatran etexilate 150 mg capsule, 60	1	5	..	96.12	36.10	Pradaxa	BY
DEGARELIX								
<u>Authority required (STREAMLINED)</u>								
3229								
Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised for the 120 mg powder for injection.								
2785N	degarelix 120 mg injection [2 x 120 mg vials] (&) inert substance diluent [2 syringes], 1 pack	1	438.93	36.10	Firmagon 120mg	FP
DEGARELIX								
<u>Authority required (STREAMLINED)</u>								
3229								
Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate								
2784M	degarelix 80 mg injection [1 x 80 mg vial] (&) inert substance diluent [1 syringe], 1 pack	1	5	..	420.41	36.10	Firmagon 80mg	FP
FLUTAMIDE								
<u>Authority required (STREAMLINED)</u>								
3674								
Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) analogue therapy								
<u>Note</u>								
No applications for increased maximum quantities and/or repeats will be authorised.								
<u>Note</u>								
Shared Care Model:								
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.								
2742H NP	flutamide 250 mg tablet, 30	3	5	..	*171.63	36.10	Flutamide MYLAN	AF
T AFLUPROST								
2755B	tafluprost 0.0015% eye drops, 30 x 0.3 mL unit doses	1	5	..	34.03	35.16	Saflutan	MK
2748P OP	tafluprost 0.0015% eye drops, 30 x 0.3 mL unit doses	1	5	..	34.03	35.16	Saflutan	MK

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed Price for Max.		Brand Name and Manufacturer
					Qty	\$	
FILGRASTIM							
<u>Authority required (STREAMLINED)</u>							
3357							
For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia							
<u>Authority required (STREAMLINED)</u>							
3358							
Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy							
<u>Authority required (STREAMLINED)</u>							
3359							
Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation							
<u>Authority required (STREAMLINED)</u>							
3360							
A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation							
<u>Authority required (STREAMLINED)</u>							
3361							
A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation							
<u>Authority required (STREAMLINED)</u>							
3368							
A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))							
<u>Authority required (STREAMLINED)</u>							
3369							
A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned							
<u>Authority required (STREAMLINED)</u>							
3362							
A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned							
<u>Authority required (STREAMLINED)</u>							
3363							
A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned							
<u>Authority required (STREAMLINED)</u>							
3364							
A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned							
<u>Authority required (STREAMLINED)</u>							
3365							
A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned							
<u>Authority required (STREAMLINED)</u>							
3366							
A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)							
<u>Authority required (STREAMLINED)</u>							
3367							
A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))							

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed Price for Max. Qty \$	Brand Name and Manufacturer	
	<u>Authority required (STREAMLINED)</u>						
	3370						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia						
	<u>Authority required (STREAMLINED)</u>						
	3371						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)						
	<u>Authority required (STREAMLINED)</u>						
	3372						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours						
	<u>Authority required (STREAMLINED)</u>						
	3373						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours						
	<u>Authority required (STREAMLINED)</u>						
	3374						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma						
	<u>Authority required (STREAMLINED)</u>						
	3375						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)						
	<u>Authority required (STREAMLINED)</u>						
	3376						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease						
	<u>Authority required (STREAMLINED)</u>						
	3377						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma						
	<u>Authority required (STREAMLINED)</u>						
	3834						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)						
2758E	filgrastim 300 microgram/0.5 mL injection, 5 x 0.5 mL syringes	4	11	..	*2515.52	Zarzio	SZ
2783L	filgrastim 480 microgram/0.5 mL injection, 5 x 0.5 mL syringes	4	11	..	*4032.56	Zarzio	SZ

RALTEGRAVIR

Authority required (STREAMLINED)

4275

HIV infection

Treatment Phase: Initial

The Clinical criteria is:

The treatment must be in combination with other antiretroviral agents,

AND the Clinical criteria is:

Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy,

AND the Clinical criteria is:

Patient must have a CD4 count of less than 500 per cubic millimetre; OR

Patient must have symptomatic HIV disease,

AND the Population criteria is:

Patient must be aged 2 years or older.

Authority required (STREAMLINED)

4274

HIV infection

Treatment Phase: Continuing

The Clinical criteria is:

The treatment must be in combination with other antiretroviral agents,

AND the Clinical criteria is:

Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy,

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer	
					Qty	Price for Max. \$		
AND the Clinical criteria is:								
Patient must have previously received PBS-subsidised therapy for HIV infection,								
AND the Population criteria is:								
Patient must be aged 2 years or older.								
2736B	raltegravir 25 mg tablet: chewable, 60	6	5	..	*506.28		ISENTRESS	MK
2760G	raltegravir 100 mg tablet: chewable, 60	6	5	..	*2025.00		ISENTRESS	MK

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed		Brand Name and Manufacturer
					Price for Max.	Qty \$	
	FILGRASTIM						
	<u>Authority required</u>						
	For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia						
	<u>Authority required</u>						
	Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy						
	<u>Authority required</u>						
	A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned						
	<u>Authority required</u>						
	A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)						
	<u>Authority required</u>						
	A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))						
	<u>Authority required</u>						
	A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))						
	<u>Authority required</u>						
	A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned						
	<u>Authority required</u>						
	Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation						
	<u>Authority required</u>						
	A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation						
	<u>Authority required</u>						
	A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation						
	<u>Authority required</u>						
	A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned						
	<u>Authority required</u>						
	A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned						
	<u>Authority required</u>						
	A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned						
	<u>Authority required</u>						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia						
	<u>Authority required</u>						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)						
	<u>Authority required</u>						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours						
	<u>Authority required</u>						
	A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours						

HIGHLY SPECIALISED DRUGS PROGRAM (Private Hospital)

Code	Name, Restriction, Manner of Administration and Form	Max. Qty (Packs)	No. of Rpts	Premium \$	Dispensed Price for Max.		Brand Name and Manufacturer	
					Qty \$			
	<u>Authority required</u> A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma							
	<u>Authority required</u> A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)							
	<u>Authority required</u> A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease							
	<u>Authority required</u> A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma							
	<u>Authority required</u> A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)							
2747N	filgrastim 300 microgram/0.5 mL injection, 5 x 0.5 mL syringes	4	11	..		*2562.15	Zarzio	SZ
2733W	filgrastim 480 microgram/0.5 mL injection, 5 x 0.5 mL syringes	4	11	..		*4079.19	Zarzio	SZ
	RALTEGRAVIR							
	<u>Authority required</u> HIV infection Treatment Phase: Initial The Clinical criteria is: The treatment must be in combination with other antiretroviral agents, AND the Clinical criteria is: Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy, AND the Clinical criteria is: Patient must have a CD4 count of less than 500 per cubic millimetre; OR Patient must have symptomatic HIV disease, AND the Population criteria is: Patient must be aged 2 years or older.							
	<u>Authority required</u> HIV infection Treatment Phase: Continuing The Clinical criteria is: The treatment must be in combination with other antiretroviral agents, AND the Clinical criteria is: Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy, AND the Clinical criteria is: Patient must have previously received PBS-subsidised therapy for HIV infection, AND the Population criteria is: Patient must be aged 2 years or older.							
2743J	raltegravir 25 mg tablet: chewable, 60	6	5	..		*533.19	Isentress	MK
2754Y	raltegravir 100 mg tablet: chewable, 60	6	5	..		*2071.65	Isentress	MK